Frontiers in Clinical Drug Research – HIV is a valuable resource for pharmaceutical scientists, clinicians and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in HIV/AIDS research.
The fifth volume of this series features 5 chapters that cover these topics:
- Clinical Eradication of Latent HIV Reservoirs: Where Are We Now?
- HIV-1 Genotypic Drug Resistance Testing and Next-Generation Sequencing
- Current and Promising Multiclass Drug Regimens and Long-Acting Formulation Drugs in HIV Therapy
- Role of Nanotechnology in HIV Diagnosis and Prognosis
- Preventive and Therapeutic Features of Combination Therapy for HIV
About the Editor:
Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria (“Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.
Keywords:
Nanotechnology for HIV control, AIDS Research, Virology, HIV-1 Protease Inhibitors, HIV reservoirs, HIV drug resistance, HAART Antiretroviral Therapy, Combination therapy for HIV, next-generation sequencing of HIV, reverse transcriptase inhibitors, HIV-1 protease inhibitors, HIV prevention, Integrase Inhibitor, Sexually Transmitted Co-infections, HIV-1 Replication Blocking, antiretroviral resistance antiretroviral efficacy.
For more information, please visit: https://bit.ly/3FilAZj